Jneid and colleagues1 have comprehensively reviewed the clinical benefits of adding clopidogrel to aspirin therapy for patients with acute non–ST-segment elevation coronary syndromes. However, their approach was flawed in terms of focusing on relative risk reductions, a ploy commonly used by the pharmaceutical industry to promote the efficacy of their products in a misleading manner.
Peterson GM, Jackson SL. Cost-effectiveness of Newer Antiplatelet Drugs. Arch Intern Med. 2003;163(20):2533–2534. doi:10.1001/archinte.163.20.2533-a